Science and Technology Resources

OSTR通过弗雷德里克国家实验室（FNL）的蛋白质表征实验室，为CCR研究人员提供了一系列哺乳动物细胞蛋白质表征分析的支持。OSTR继续评估所有商业上可用的蛋白质和基因表达谱平台以及其他高通量技术。为了使CCR研究人员更容易获得最新的进展，OSTR与提供基因组和代谢组学分析技术和服务的公司建立了许多安排。这些协议大大降低了CCR研究人员获取这些技术的成本和效率。已经建立了一项补贴计划，为CCR研究者提供补贴，以支持他们获得先进的基因组学、蛋白质组学、代谢组学和生物信息学技术。这种资助机制有助于扩大CCR实验室可用的有限研究资金，并允许我们的研究人员进行原本可能成本过高的实验。许多受资助的项目都在顶级期刊上发表了重要论文。最近，OSTR参与了CCR获得下一代测序技术的努力，包括建立一个新的单细胞分析设施，现在位于41号楼，可供任何CCR研究者使用。为了应对CCR对管理和分析大量基因组和蛋白质组学数据的快速增长的需求，OSTR与一些生物信息学公司建立了合作关系。为了显著节省NCI的成本，OSTR代表所有NCI研究人员谈判了各种许可协议，以便普遍获得用于微阵列实验、蛋白质组学分析研究和基因组分析（包括下一代测序数据）的生物信息学和统计分析的复杂工具。此外，OSTR还为所有NCI提供了一些用于研究通路和生物关联网络的软件应用程序。OSTR继续评估CCR在生物信息学和生物统计学领域的要求。我们继续与Leidos生物医学研究（LBR）合作，创建一个专门的CCR生物信息学计划，为CCR研究人员提供支持。这个位于贝塞斯达校区的新项目支持高通量基因组和蛋白质组学数据的分析。最近，OSTR负责管理协同蛋白质技术资源的纳米级蛋白质组学部分。该中心面向所有CCR研究人员开放，致力于开发和实施基于蛋白质的尖端技术，以促进CCR/NCI/NIH的发现、转化和临床研究。该核心提供专业知识，并提供最先进的技术，以适应CCR/NCI/NIH研究人员的需求：快速，精确的蛋白质分析；全面定量的细胞信号事件解剖；纳米尺度定量蛋白质组学评估；生物标志物开发和治疗靶点鉴定；临床应用分析的开发和应用。最近，CPTR正在向CCR社区提供空间蛋白质组学和转录组学。本核心单独报告。

The OSTR is supporting a number of protein characterization analyses in mammalian cells for CCR investigators through the Laboratory of Protein Characterization at the Frederick National Lab (FNL). The OSTR continues to evaluate all commercially available platforms for protein and gene expression profiling and other high throughput technologies. To make the latest advances easily accessible to CCR researchers, the OSTR has established a number of arrangements with companies providing genomic and metabolomic profiling technologies and services. These agreements have led to far lower cost and an efficient and easy way for CCR investigators to access these technologies. A subsidy program has been established providing subsidies to support CCR investigator access to advanced genomic, proteomic, metabolomic, and bioinformatic technologies. This funding mechanism has helped to extend the limited research dollars available to CCR laboratories and has permitted our researchers to conduct experiments that might otherwise be cost prohibitive. Many of the funded projects have led to important publications in top-tier journals. Most recently, the OSTR has been involved in CCR's efforts to access the next generation sequencing technologies, including the setting up of a new single cell analysis facility now located building 41, which is available to any CCR investigator. In response to CCR's rapidly growing need to manage and analyze large sets of genomic and proteomic data, the OSTR has developed several partnerships with bioinformatics companies. At significant cost savings to NCI, OSTR negotiated a variety of license agreements on behalf of all NCI researchers for universal access to sophisticated tools for bioinformatic and statistical analysis of microarray experiments, proteomic profiling studies, and genomic analysis including next-generation sequencing data. In addition, the OSTR has made a number of software applications for the investigation of pathways and biological association networks available to all of NCI. The OSTR continues to assess CCR's requirements in the area of bioinformatics and biostatistics. We continue to work with Leidos Biomedical Research (LBR) to create a CCR dedicated Bioinformatics Program to provide support to CCR investigators. Support for analysis of high throughput genomic and proteomic data is being made available through this new program, which is located on the Bethesda campus. Most recently, the OSTR has taken on the management of the NanoScale Proteomics section of the Collaborative Protein Technology Resource. This Core is an open to all CCR investigators and dedicated to developing and implementing cutting-edge protein-based technologies to facilitate discovery, translational and clinical research in CCR/NCI/NIH. This Core offers expertise and provides state-of-the-art technologies to accommodate the demands of CCR/NCI/NIH investigators for: Rapid and precise protein analysis; Comprehensive and quantitative cell signaling event dissection; Nanoscale quantitative proteomics assessment; Biomarker development and therapeutic target identification; and, Clinical applicable assay development and applications. Most recently, the CPTR is offering spatial proteomics and transcriptomics to the CCR community. This Core is reported separately.